Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Publication Date Jun 2012
Publisher GlobalData
Product Type Report
Pages 75
Single User License $ 3995.00
Site User License $ 7990.00
Corporate User License $ 11985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report identifies the key trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gastrointestinal Stromal Tumors (GIST) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Gastrointestinal Stromal Tumors (GIST) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gastrointestinal Stromal Tumors (GIST) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Gastrointestinal Stromal Tumors (GIST) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market landscape? – Identify, understand and capitalize.


Companies Mentioned

Novartis AG AB Science Bayer AG

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Gastrointestinal Stromal Tumors Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 9
2.5 Staging of Gastrointestinal Stromal Tumors 10
2.6 Diagnosis of Gastrointestinal Stromal Tumors 10
2.6.1 Computed Tomography Scan 10
2.6.2 Barium Swallow 11
2.6.3 Magnetic Resonance Imaging or Positron Emission Tomography 11
2.6.4 Mutational Analysis 11
2.7 Treatment of Gastrointestinal Stromal Tumors 11
2.7.1 Surgery 11
2.7.2 Radiation Therapy 12
2.7.3 Chemotherapy 12
2.7.4 Targeted Therapy 12
2.8 Treatment and Management Pattern 13
2.9 Referral Pathway 14
2.10 GlobalData Pipeline Report Guidance 15
3 Gastrointestinal Stromal Tumors Therapeutics - Market Characterization 16
3.1 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Global 16
3.2 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Global 18
3.3 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – The US 20
3.4 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – The US 21
3.5 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – The UK 22
3.6 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – The UK 23
3.7 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – France 24
3.8 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – France 25
3.9 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Germany 26
3.10 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Germany 27
3.11 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Italy 28
3.12 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Italy 29
3.13 Gastrointestinal Stromal Tumors Therapeutics Market Size (2006–2011) – Spain 30
3.14 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Spain 31
3.15 Gastrointestinal Stromal Tumors Market Size (2006–2011) – Japan 32
3.16 Gastrointestinal Stromal Tumors Therapeutics Market Forecast (2011–2019) – Japan 33
3.17 Drivers and Barriers for the Gastrointestinal Stromal Tumors Market 34
3.17.1 Drivers for the Gastrointestinal Stromal Tumors Market 34
3.17.2 Barriers for the Gastrointestinal Stromal Tumors Therapeutics Market 35
3.18 Opportunity and Unmet Need 36
3.19 Key Takeaway 37
4 Gastrointestinal Stromal Tumors Therapeutics - Competitive Assessment 38
4.1 Overview 38
4.2 Strategic Competitor Assessment 38
4.3 Marketed Product Profile 39
4.3.1 Gleevec (imatinib mesylate) 39
4.3.2 Sutent (sunitinib malate) 41
4.4 Key Takeaway 43
5 Gastrointestinal Stromal Tumors Therapeutics - Pipeline Assessment 44
5.1 Overview 44
5.2 Strategic Pipeline Assessment 44
5.3 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis – Pipeline by Clinical Phase of Development 45
5.3.1 Gastrointestinal Stromal Tumors Therapeutics – Phase III Clinical Pipeline 45
5.3.2 Gastrointestinal Stromal Tumors Therapeutics – Phase II/III Clinical Pipeline 46
5.3.3 Gastrointestinal Stromal Tumors Therapeutics – Phase II Clinical Pipeline 46
5.3.4 Gastrointestinal Stromal Tumors Therapeutics – Phase I/II Clinical Pipeline 46
5.3.5 Gastrointestinal Stromal Tumors Therapeutics – Phase I Clinical Pipeline 47
5.3.6 Gastrointestinal Stromal Tumors Therapeutics – Preclinical Phase 47
5.4 Gastrointestinal Stromal Tumors Therapeutics Pipeline Analysis - Pipeline by Mechanism of Action 48
5.5 Gastrointestinal Stromal Tumors Technology Trends Analytical Framework 49
5.6 Molecule Profile for Late-stage Molecules under Clinical Development 50
5.6.1 Masitinib 50
5.6.2 Nexavar (sorafenib) 51
5.6.3 Regorafenib (BAY 73-4506) 52
5.6.4 Tasigna (nilotinib) 53
5.7 Key Takeaway 53
6 Gastrointestinal Stromal Tumors Therapeutics – Clinical Trial Mapping 54
6.1 Clinical Trial Mapping by Country (The US, EU5 and Japan) 54
6.2 Clinical Trial Mapping by Phase 55
6.3 Clinical Trial Mapping by Trial Status 56
6.4 Clinical Trial Mapping Overall Sponsors 57
6.5 Clinical Trial Mapping by Prominent Sponsors 58
6.6 Clinical Trial Mapping by Companies 59
7 Gastrointestinal Stromal Tumors Therapeutics - Strategic Assessment 60
7.1 Gastrointestinal Stromal Tumors Therapeutics: Implications for Future Market Competition 60
8 Gastrointestinal Stromal Tumors Therapeutics - Future Players in the Market 62
8.1 Introduction 62
8.2 Company Profiles 62
8.2.1 Novartis AG 62
8.2.2 AB Science 63
8.2.3 Bayer AG 64
8.3 Gastrointestinal Stromal Tumors Therapeutics Market – Other Future Players 65
9 Gastrointestinal Stromal Tumors Therapeutics - Licensing and Partnership Deals 67
10 Gastrointestinal Stromal Tumors Therapeutics - Appendix 68
10.1 Definitions 68
10.2 Acronyms 68
10.3 Bibliography 69
10.4 Research Methodology 71
10.4.1 Coverage 71
10.4.2 Secondary Research 72
10.4.3 Forecasting 72
10.4.4 Primary Research 74
10.4.5 Expert Panel Validation 75
10.5 Contact Us 75
10.6 Disclaimer 75

List of Tables
1.1 List of Tables
Table 1: Historical Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2006–2011 (approximate) 8
Table 2: Forecast Prevalence of Gastrointestinal Stromal Tumors in Seven Major Markets, 2011–2019 (approximate) 9
Table 3: Occurrence Rate of Symptoms of Gastrointestinal Stromal Tumors, 2010 9
Table 4: TNM Staging, Gastrointestinal Stromal Tumors, 2011 10
Table 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006–2011 16
Table 6: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011–2019 18
Table 7: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006–2011 20
Table 8: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011–2019 21
Table 9: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006–2011 22
Table 10: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011–2019 23
Table 11: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006–2011 24
Table 12: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011–2019 25
Table 13: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006–2011 26
Table 14: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011–2019 27
Table 15: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006–2011 28
Table 16: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011–2019 29
Table 17: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006–2011 30
Table 18: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011–2019 31
Table 19: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006–2011 32
Table 20: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011–2019 33
Table 21: Gastrointestinal Stromal Tumors Efficacy Results, Sutent 42
Table 22: Gastrointestinal Stromal Tumors Therapeutics – Phase III Pipeline 45
Table 23: Gastrointestinal Stromal Tumors Therapeutics – Phase II/III Pipeline 46
Table 24: Gastrointestinal Stromal Tumors Therapeutics – Phase II Pipeline 46
Table 25: Gastrointestinal Stromal Tumors Therapeutics – Phase I/II Pipeline 46
Table 26: Gastrointestinal Stromal Tumors Therapeutics – Phase I Pipeline 47
Table 27: Gastrointestinal Stromal Tumors Therapeutics – Preclinical Phase 47
Table 28: Nexavar Phase II Trial – Summary of Results, 2011 52
Table 29: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Country, 2012 54
Table 30: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Phase, 2012 55
Table 31: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Status, 2012 56
Table 32: Gastrointestinal Stromal Tumors Therapeutics, Overall Sponsors, 2012 57
Table 33: Gastrointestinal Stromal Tumors Therapeutics – Prominent Sponsors, 2012 58
Table 34: Gastrointestinal Stromal Tumors Therapeutics – Companies, 2012 59
Table 35: Gastrointestinal Stromal Tumors Pipeline, Novartis AG 63
Table 36: Gastrointestinal Stromal Tumors Pipeline, AB Science 64
Table 37: Gastrointestinal Stromal Tumors Pipeline, Bayer AG 64
Table 38: Gastrointestinal Stromal Tumors Therapeutics, Other Future Players 65
Table 39: Gastrointestinal Stromal Tumors Therapeutics, Global, Deals, 2012 67

List of Figures
1.2 List of Figures
Figure 1: Distribution of Gastrointestinal Stromal Tumors 7
Figure 2: Patient Share of Gastrointestinal Stromal Tumors in the Seven Major Markets, 2011 8
Figure 3: Gastrointestinal Stromal Tumors Therapeutics – Treatment Algorithm 13
Figure 4: Referral Pathway for Gastrointestinal Stromal Tumors 14
Figure 5: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Revenue ($m), 2006–2011 16
Figure 6: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2011 17
Figure 7: Gastrointestinal Stromal Tumors Therapeutics Market, Global, Forecast ($m), 2011–2019 18
Figure 8: Gastrointestinal Stromal Tumors Therapeutics, Global Market Share ($m), 2019 19
Figure 9: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Revenue ($m), 2006–2011 20
Figure 10: Gastrointestinal Stromal Tumors Therapeutics Market, The US, Forecast ($m), 2011–2019 21
Figure 11: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Revenue ($m), 2006–2011 22
Figure 12: Gastrointestinal Stromal Tumors Therapeutics Market, The UK, Forecast ($m), 2011–2019 23
Figure 13: Gastrointestinal Stromal Tumors Therapeutics Market, France, Revenue ($m), 2006–2011 24
Figure 14: Gastrointestinal Stromal Tumors Therapeutics Market, France, Forecast ($m), 2011–2019 25
Figure 15: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Revenue ($m), 2006–2011 26
Figure 16: Gastrointestinal Stromal Tumors Therapeutics Market, Germany, Forecast ($m), 2011–2019 27
Figure 17: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Revenue ($m), 2006–2011 28
Figure 18: Gastrointestinal Stromal Tumors Therapeutics Market, Italy, Forecast ($m), 2011–2019 29
Figure 19: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Revenue ($m), 2006–2011 30
Figure 20: Gastrointestinal Stromal Tumors Therapeutics Market, Spain, Forecast ($m), 2011–2019 31
Figure 21: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Revenue ($m), 2006–2011 32
Figure 22: Gastrointestinal Stromal Tumors Therapeutics Market, Japan, Forecast ($m), 2011–2019 33
Figure 23: Drivers and Barriers for Gastrointestinal Stromal Tumor Therapeutics, 2012 35
Figure 24: Opportunity and Unmet Need in the Primary (Resectable) Gastrointestinal Stromal Tumors Therapeutics Market, 2012 36
Figure 25: Opportunity and Unmet Need in the Metastatic/Unresectable Gastrointestinal Stromal Tumors Therapeutics Market, 2012 37
Figure 26: Gastrointestinal Stromal Tumors Therapeutics Market – Strategic Competitor Assessment, 2012 39
Figure 27: Gleevec Phase III Trial Results – Progression-free Survival 40
Figure 28: Gleevec Phase III Trial Results – Overall Response Rate 41
Figure 29: Sutent – Time to Tumor Progression in Gastrointestinal Stromal Tumor Patients 42
Figure 30: Gastrointestinal Stromal Tumors Therapeutics – Pipeline by Phase of Development, 2012 45
Figure 31: Gastrointestinal Stromal Tumors Therapeutics – Clinical Pipeline by Mechanism of Action, 2012 48
Figure 32: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012 49
Figure 33: Technology Trends Analytical Framework of the Gastrointestinal Stromal Tumors Pipeline, 2012 50
Figure 34: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Country, 2012 54
Figure 35: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Phase, 2012 55
Figure 36: Gastrointestinal Stromal Tumors Therapeutics – Clinical Trials by Status, 2012 56
Figure 37: Gastrointestinal Stromal Tumors Therapeutics – Overall Sponsors, 2012 57
Figure 38: Gastrointestinal Stromal Tumors Therapeutics – Prominent Sponsors, 2012 58
Figure 39: Gastrointestinal Stromal Tumors Therapeutics – Companies, 2012 59
Figure 40: Implications for Future Market Competition in the Gastrointestinal Stromal Tumors Therapeutics Market, 2012 60
Figure 41: Gastrointestinal Stromal Tumors Therapeutics – Future Players, 2012 62
Figure 42: GlobalData Market Forecasting Model 74

Title Date Price
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Medical Devices Market in Russia 2009-2013
By Infiniti Research Ltd
Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
Mar 2010 $1500.00
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances Profile
By GlobalData
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances ProfileSummary20/10 Perfect Vision AG is engaged in the development, manufacturing and marketing of innovative technologies for raisi ...Read More
Jan 2012 $250.00
2010 U.S. Ambulatory Surgical & Emergency Centers Industry Report
By Barnes Reports
The U.S Ambulatory Surgical & Emergency Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...Read More
Jan 2010 $149.00
2010 U.S. Biological Product Manufacturing Industry Report
By Barnes Reports
The U.S. Biological Product Manufacturing Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 ...Read More
Jan 2010 $149.00
2010 U.S. HMO Medical Centers Industry Report
By Barnes Reports
The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
Jan 2010 $149.00
2010 U.S. Home Health Care Services Industry Report
By Barnes Reports
The Home Health Care Services Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and ...Read More
Oct 2009 $149.00
2010 U.S. Kidney Dialysis Centers Industry Report
By Barnes Reports
The U.S Kidney Dialysis Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current an ...Read More
Jan 2010 $149.00
2010 U.S. Medical & Surgical Hospitals Industry Report
By Barnes Reports
The Medical & Surgical Hospitals Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current a ...Read More
Oct 2009 $149.00
2010 U.S. Medical Laboratories Industry Report
By Barnes Reports
The Medical Laboratories Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 2011 ...Read More
Oct 2009 $149.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z